Nakamura Tomoki, Hagi Tomohito, Asanuma Kunihiro, Sudo Akihiro
Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu 514-8507, Japan.
Cancers (Basel). 2022 Oct 24;14(21):5214. doi: 10.3390/cancers14215214.
Background: Recently, the lymphocyte-to-CRP ratio (LCR) was found to have a prognostic role in many cancers. However, the clinical significance of LCR in patients with soft tissue sarcoma (STS) has not yet been established. This study aimed to determine whether LCR can predict disease-specific survival (DSS) and event-free survival (EFS) in patients with STS. Methods: In this study, 132 patients were enrolled. The mean follow-up periods were 76.5 months. Blood examinations were performed prior to treatment for all patients. Results: The 5-year DSS in patients with higher and lower LCR was 86.5% and 52.8%, respectively (p < 0.001). Patients with lower LCR had worse survival than those with higher LCR. The 5-year EFS in patients with higher and lower LCR was 66.2% and 31.2%, respectively (p < 0.001). On Receiver operating characteristic analysis, however, there was no significant difference in the area under curve (AUC) between CRP level (AUC = 0.72) and LCR (AUC = 0.711). Conclusions: LCR may be a prognostic factor for predicting oncological events in multivariate analysis, although ROC analysis could not show the superiority of LCR to CRP for predicting oncological outcomes in patients with STS.
最近，淋巴细胞与C反应蛋白比值（LCR）被发现对多种癌症具有预后作用。然而，LCR在软组织肉瘤（STS）患者中的临床意义尚未明确。本研究旨在确定LCR是否能预测STS患者的疾病特异性生存（DSS）和无事件生存（EFS）。方法：本研究纳入了132例患者。平均随访期为76.5个月。所有患者在治疗前均进行了血液检查。结果：LCR较高和较低的患者5年DSS分别为86.5%和52.8%（p<0.001）。LCR较低的患者生存率低于LCR较高的患者。LCR较高和较低的患者5年EFS分别为66.2%和31.2%（p<0.001）。然而，在接受者操作特征分析中，CRP水平（曲线下面积[AUC]=0.72）和LCR（AUC=0.711）之间的曲线下面积没有显著差异。结论：在多变量分析中，LCR可能是预测肿瘤事件的一个预后因素，尽管ROC分析未能显示LCR在预测STS患者肿瘤结局方面优于CRP。
